IOM. 2011b. The new profile of drug-resistant tuberculosis in Russia: A global and local perspective: Workshop summary. Washington, DC: The National Academies Press.

IOM. 2012. Facing the reality of drug-resistant tuberculosis in India: Challenges and potential solutions: Workshop summary. Washington, DC: The National Academies Press.

Keshavjee, S. 2012. Background on the Green Light Committee and the second line tuberculosis drug supply chain. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Keshavjee, S., and P. Farmer. 2012. Tuberculosis, drug resistance, and the history of modern medicine. New England Journal of Medicine 367(10):931-936.

Keshavjee, S., and K. Seung. 2008. Stemming the tide of multidrug-resistant tuberculosis: Major barriers to addressing the growing epidemic. http://www.iom.edu/~/media/Files/Activity%20Files/Research/DrugForum/IOM_MDRTB_whitepaper_2009_01_14_FINAL_Edited.pdf (accessed September 15, 2011).

Kimerling, M. 2012. SLD Financing Issues: IOM workshop on the global supply chain for second-line drugs for MDR-TB. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Mostaghim, S. 2012. MDR-TB drugs: Challenges and barriers to efficient operation of existing supply chain. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

MSF (Médecins Sans Frontières) and IUATLD (International Union Against Tuberculosis and Lung Disease). 2011. DR-TB drugs under the microscope: Sources and prices for drugresistant tuberculosis medicines. http://www.msfaccess.org/our-work/addressing-medicalchallenges/article/888 (accessed October 1, 2012).

MSH (Management Sciences for Health). 2011. Quality assurance for pharmaceuticals. http://www.msh.org/resource-center/publications/upload/MDS3-Ch19-QualityAssuranceNov2011.pdf (accessed November 13, 2012).

Ripin, D. 2012. Lessons learned from catalyzing and sustaining access to pediatric HIV treatments. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Sims, T. 2012. Creating innovative solutions for MDR-TB: Ideas from the MDR-TB innovation summit. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Wallengren, K., F. Scano, P. Nunn, B. Margot, S. Buthelezi, B. Williams, A. Pym, E. Y. Samuel, F. Mirzayev, W. Nkhoma, L. Mvusi, and Y. Pillay. 2011. Drug-resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007. Emerging Infectious Diseases 17(10):1913-1916.

Walsh, J. A., and K. S. Warren. 1979. Selective primary health care: An interim strategy for disease control in developing countries. New England Journal of Medicine 301(18):967-974. WHO (World Health Organization). 2006. Guidelines for the programmatic management of drug-resistant tuberculosis. http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf (accessed October 1, 2012).

WHO. 2010. Global Tuberculosis Control: WHO report 2010. http://www.who.int/tb/publications/global_report/2010/en/index.html (accessed September 18, 2011).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement